SCHEMBL4331569

SCHEMBL4331569

Clc1cncc(-c2cc(-c3cccc(Cl)c3)on2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 10/20 0.53
RAB9A P51151 10/20 0.53
NOTUM Q6P988 1/20 0.49
TP53 P04637 3/20 0.47
MAPT P10636 2/20 0.47
POLB P06746 1/20 0.47
HSD17B1 P14061 1/20 0.47
HSD17B2 P37059 1/20 0.47
MAOB P27338 1/20 0.44
THRB P10828 1/20 0.44
MAPK1 P28482 1/20 0.43
CXCR1 P25024 1/20 0.43
ALDH1A1 P00352 1/20 0.42
CASP3 P42574 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
SENP6 Q9GZR1 1/20 0.42
MITF O75030 1/20 0.42
PKM P14618 1/20 0.42
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4322944 0.89 NPC1 (0.67) NPC1RAB9ANOTUMTP53CXCR1
SCHEMBL4325666 0.89 RAB9A (0.48) NPC1RAB9ANOTUMTP53MAPT
SCHEMBL4316645 0.87 CYP2C9 (0.53) NPC1RAB9ATP53MAPTPOLB
SCHEMBL4324167 0.87 MAPT (0.62) NPC1RAB9ANOTUMTP53MAPT
SCHEMBL4318582 0.84 NPC1 (0.64) NPC1RAB9ANOTUMMAPTCXCR1
SCHEMBL17084388 0.84 NPC1 (0.73) NPC1RAB9ANOTUMTP53MAPT
SCHEMBL4323854 0.84 NPC1 (0.48) NPC1RAB9ANOTUMMAPTPOLB
SCHEMBL4327155 0.82 NPC1 (0.47) NPC1RAB9AMAPTHSD17B1HSD17B2
SCHEMBL28677426 0.81 NPC1 (0.73) NPC1RAB9ANOTUMTP53MAPT
SCHEMBL30423208 0.81 NPC1 (0.73) NPC1RAB9ANOTUMTP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383658-B2 Isoxazole based neuronal nicotinic receptor ligands and methods of use ABBOTT LABORATORIES (US) 2013-02-26 US claimed
WO-2009149135-A1 BIS (HETERO ) ARYL SUBSTITUTED ISOXAZOLES FOR USE AS NEURONAL NICOTINIC RECEPTOR MODULATORS ABBOTT LABORATORIES (US) 2009-12-10 WO claimed
US-20090306096-A1 Novel Isoxazoles and Methods of Use Thereof ABBOTT LABORATORIES (US) 2009-12-10 US claimed
US-8383658-B2 Isoxazole based neuronal nicotinic receptor ligands and methods of use ABBOTT LABORATORIES (US) 2013-02-26 US disclosed
WO-2009149135-A1 BIS (HETERO ) ARYL SUBSTITUTED ISOXAZOLES FOR USE AS NEURONAL NICOTINIC RECEPTOR MODULATORS ABBOTT LABORATORIES (US) 2009-12-10 WO disclosed
US-20090306096-A1 Novel Isoxazoles and Methods of Use Thereof ABBOTT LABORATORIES (US) 2009-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306096-A1 Novel Isoxazoles and Methods of Use Thereof XDH, PRDX5, CYP4X1 NPC1 837/4885RAB9A 4160/4885NOTUM 2220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.